喷雾干燥Eudragit® E-PO与乙氨基使用2和3流体喷嘴进行口味掩饰
Linda A Felton1, Gülşilan Binzet2, Cody Wiley1
1University of New Mexico College of Pharmacy, MSC09 5360, 1 University of New Mexico, Albuquerque, NM 87131, USA.
International journal of pharmaceutics
|May 3, 2024
概括
用Eudragit® E-PO使用3流体喷嘴喷雾干燥亚美诺芬并没有有效地掩盖味道. 像Eudragit® L 100-55这样的替代聚合物改善了口味掩饰的产量和药物释放概况.
科学领域:
- 制药技术 制药技术 制药技术
- 材料科学 材料科学 材料科学
背景情况:
- 传统的喷雾干燥通常会导致苦药的味道掩盖不好.
- 三流体喷嘴喷雾干燥为改善材料封装提供了潜力.
研究的目的:
- 通过使用Eudragit® E-PO (EE) 通过2和3流体喷嘴喷雾干燥来评估乙氨基 (APAP) 的口味掩饰.
- 研究不同聚合物和喷嘴配置对产量和药物释放的影响.
主要方法:
- 用Eudragit® E-PO,Eudragit® L 100-55或Methocel® E6使用2和3流体喷嘴喷雾干燥亚美诺芬.
- 微粒子产量和体外药物释放概况的分析.
主要成果:
- 当使用APAP喷雾干燥EE时,无论喷嘴类型如何,都观察到低产率 (≤13%).
- 使用Eudragit® L 100-55或Methocel® E6.5显著改善了产量.
- 使用2流体喷嘴的药物释放速度更快,使用EE在3流体喷嘴的外流中更慢,尽管不完整.
结论:
- 选择的聚合物和喷嘴配置显著影响微粒的产量和药物释放.
- 用特定的聚合物进行三流体喷嘴喷雾干燥显示了口味掩饰的潜力,但完全封装需要进一步优化.
更多相关视频
10:12Flash NanoPrecipitation for the Encapsulation of Hydrophobic and Hydrophilic Compounds in Polymeric Nanoparticles
Published on: January 7, 2019
22.1K
04:59Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
Published on: August 18, 2023
843
相关概念视频
In Vitro Drug Dissolution: Compendial Testing Models II
686
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
686
Oral Drug Delivery Systems: Delayed-Release Systems
222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222
